Immutep Receives A$2.16 million French R&D Tax Incentive
The funding adds cash without issuing shares and will support current research on eftilagimod alfa and IMP761.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Immutep (NASDAQ: IMMP) has received approximately A$2.16 million from the French Government as a tax incentive for research and development. The payment of €1.36 million covers eligible activities conducted in calendar year 2025 under the Crédit d’Impôt Recherche program, which refunds 30% of eligible expenditure.
The non-dilutive funding will support current research and development for eftilagimod alfa (efti) and IMP761. It follows an A$0.86 million Australian cash rebate announced on 30 September 2026. Immutep expects its cash reach to extend into the first half of CY2028.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Moderate pointFrench research tax incentive provides €1.36 million (approximately A$2.16 million) in non-dilutive cash funding.
- Moderate point. Forward-looking: it has not happened yet and may not happen.Immutep expects its cash reach to extend into the first half of CY2028.
- Minor pointAustralian research tax incentive previously provided an A$0.86 million cash rebate, announced on 30 September 2026.
- Minor pointGerman subsidiary Immutep GmbH is eligible for Germany’s research and development tax incentive.
Negative
- None.
Details
Market move: IMMP +6.98% vs previous close. French R&D tax incentive
On Oct 28, the day this news came out, the latest delayed price for IMMP is 6.98% above the previous close. Our momentum scanner has recorded 5 alerts for this stock so far that day. The latest delayed price is $3.37. Relative volume is elevated at 2.0x the average.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
- French CIR payment
- A$2.16 million
- Payment for eligible calendar-year 2025 R&D activities
- Eligible R&D expenditure refund
- 30%
- French Government CIR program
- Australian R&D rebate
- A$0.86 million
- Previously received; announced September 30, 2026
- Expected cash reach
- First half of CY2028
- Company expectation
Historical Context
-
Australian tax rebate funded efti and IMP761 and supported cash reach into first half of CY2028.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
non-dilutive funding financial
lag-3 medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
SYDNEY, AUSTRALIA, Oct. 28, 2026 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage immunotherapy company targeting cancer and autoimmune diseases, today announced that it has received a cash payment of
The CIR is a French Government incentive that refunds companies
The CIR payment follows Immutep’s receipt of A
The non-dilutive funding will be applied to Immutep’s current R&D activities for its product candidates, eftilagimod alfa (efti) and IMP761.
Immutep’s expected cash reach extends into the first half of CY2028.
About Immutep
Immutep is a clinical-stage biotechnology company developing novel immunotherapies for cancer and autoimmune disease. The Company is a pioneer in the understanding and advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), and its diversified product portfolio harnesses LAG-3’s ability to stimulate or suppress the immune response. Immutep is dedicated to leveraging its expertise to bring innovative treatment options to patients in need and to maximise value for shareholders. For more information, please visit www.immutep.com.
Forward-Looking Statements
This press release contains forward-looking statements, including statements regarding the Company’s expected cash reach, the anticipated use of R&D tax incentive funding, anticipated clinical development, regulatory progress and the potential benefits of eftilagimod alfa (efti) and IMP761. These forward-looking statements are based on current expectations, estimates and projections, and involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from those expressed or implied in such statements. Factors that could cause actual results to differ materially include risks associated with clinical trial outcomes, the ongoing root cause analysis, manufacturing, regulatory developments, the outcome of partnering discussions, and the Company’s ability to obtain additional funding and to advance its product candidates. Additional risks are described in the Company’s most recent Annual Report on Form 20-F and subsequent filings with the U.S. Securities and Exchange Commission and in announcements lodged with the ASX. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date of this release. Immutep undertakes no obligation to update or revise such statements, except as required by applicable law.
Disclaimer
This announcement has been prepared for informational purposes only and does not constitute an offer to sell, or a solicitation of an offer to buy, securities in any jurisdiction.
This announcement was authorised for release by the CEO of Immutep Limited.
Australian Investors/Media:
Eleanor Pearson, Sodali & Co.
+61 2 9066 4071; eleanor.pearson@sodali.com
US Investors/Media:
Matthew Beck, astr partners
+1 (917) 415-1750; matthew.beck@astrpartners.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How much French research tax incentive funding did Immutep receive?
Immutep received €1.36 million (approximately A$2.16 million) for eligible research and development activities conducted in calendar year 2025. The non-dilutive funding will support current work on eftilagimod alfa (efti) and IMP761.
How does Immutep qualify for the French research tax incentive?
Immutep qualifies through its French subsidiary, Immutep S.A.S., which conducts research at its laboratory in France. The Crédit d’Impôt Recherche program refunds companies 30% of their eligible research and development expenditure.